IL-17 protects T cells from apoptosis and contributes to development of ALPS-like phenotypes

Blood

Volumn 123, Issue 8, 2014, Pages 1178-1186

  Boggio, Elena ^a   Clemente, Nausicaa ^a   Mondino, Anna ^b   Cappellano, Giuseppe ^a   Orilieri, Elisabetta ^a   Gigliotti, Casimiro L ^a   Toth, Erika ^a   Ramenghi, Ugo ^b   Dianzani, Umberto ^a   Chiocchetti, Annalisa ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR6; FAS ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 17AF; INTERLEUKIN 17F; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; UNCLASSIFIED DRUG; IL17A PROTEIN, HUMAN; IL17F PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; AUTOIMMUNITY; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DIANZANI AUTOIMMUNE LYMPHOPROLIFERATIVE DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PASSIVE IMMUNIZATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL TIME; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH17 CELL; ANIMAL; BLOOD; CELL CULTURE; CHILD; CYTOLOGY; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; MALE; MOUSE; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; PATHOLOGY; PRESCHOOL CHILD; YOUNG ADULT;

ANIMALS; ANTIBODIES, NEUTRALIZING; APOPTOSIS; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOPHENOTYPING; INTERLEUKIN-17; MALE; MICE; MICE, INBRED MRL LPR; PHENOTYPE; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84897900832     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-07-518167     Document Type: Article

References (50)

1. Straus SE, Sneller M, Lenardo MJ, Puck JM, Strober W. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Intern Med. 1999;130(7):591-601. (Pubitemid 29169388)
2. Bleesing JJ, Brown MR, Dale JK, et al. TcR-alpha/beta(+) CD4(-)CD8(-) T cells in humans with the autoimmune lymphoproliferative syndrome express a novel CD45 isoform that is analogous to murine B220 and represents a marker of altered O-glycan biosynthesis. Clin Immunol. 2001;100(3):314-324.
3. Oliveira JB, Bleesing JJ, Dianzani U, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010;116(14):e35-e40.
4. Dianzani U, Bragardo M, DiFranco D, et al. Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity/lymphoproliferation. Blood. 1997;89(8):2871-2879. (Pubitemid 27172574)
5. Ramenghi U, Bonissoni S, Migliaretti G, et al. Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer. Blood. 2000;95(10):3176-3182. (Pubitemid 30321170)
6. Chiocchetti A, Indelicato M, Bensi T, et al. High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lymphoproliferation. Blood. 2004;103(4):1376-1382. (Pubitemid 38168652)
7. Boggio E, Indelicato M, Orilieri E, et al. Role of tissue inhibitor of metalloproteinases-1 in the development of autoimmune lymphoproliferation. Haematologica. 2010;95(11):1897-1904.
8. Clementi R, Dagna L, Dianzani U, et al. Variations of the perforin gene in patients with autoimmunity/lymphoproliferation and defective Fas function. Blood. 2006;108(9):3079-3084.
9. Aricò M, Boggio E, Cetica V, et al. Variations of the UNC13D gene in patients with autoimmune lymphoproliferative syndrome. PLoS ONE. 2013;8(7):e68045.
10. Boggio E, Aricò M, Melensi M, et al. Mutation of FAS, XIAP, and UNC13D genes in a patient with a complex lymphoproliferative phenotype. Pediatrics. 2013;132(4):e1052-e1058.
11. Shinohara ML, Kim JH, Garcia VA, Cantor H. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity. 2008;29(1):68-78.
12. Gaffen SL. An overview of IL-17 function and signaling. Cytokine. 2008;43(3):402-407.
13. Spolski R, Leonard WJ. Cytokine mediators of Th17 function. Eur J Immunol. 2009;39(3):658-661.
14. Chen Z, O'Shea JJ. Regulation of IL-17 production in human lymphocytes. Cytokine. 2008;41(2):71-78.
15. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485-517.
16. Wright JF, Bennett F, Li B, et al. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol. 2008;181(4):2799-2805.
17. Mesturini R, Gigliotti CL, Orilieri E, et al. Differential induction of IL-17, IL-10, and IL-9 in human T helper cells by B7h and B7.1. Cytokine. 2013;64(1):322-330.
18. Niu X, He D, Zhang X, et al. IL-21 regulates Th17 cells in rheumatoid arthritis. Hum Immunol. 2010;71(4):334-341.
19. Mesquita D Jr, Cruvinel WM, Câmara NOS, Kállas EG, Andrade LEC. Autoimmune diseases in the TH17 era. Braz J Med Biol Res. 2009;42(6):476-486.
20. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8(4):345-350. (Pubitemid 46745409)
21. Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol. 2006;177(1):566-573. (Pubitemid 43939170)
22. Durelli L, Conti L, Clerico M, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-β. Ann Neurol. 2009;65(5):499-509.
23. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol. 2008;127(3):385-393.
24. Doreau A, Belot A, Bastid J, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol. 2009;10(7):778-785.
25. Chen XQ, Yu YC, Deng HH, et al. Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity. J Clin Immunol. 2010;30(2):221-225.
26. Zhao XF, Pan HF, Yuan H, et al. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep. 2010;37(1):81-85.
27. Fang Y, Yu S, Ellis JS, Sharav T, Braley-Mullen H. Comparison of sensitivity of Th1, Th2, and Th17 cells to Fas-mediated apoptosis. J Leukoc Biol. 2010;87(6):1019-1028.
28. Rana A, Minz RW, Aggarwal R, Anand S, Pasricha N, Singh S. Gene expression of cytokines (TNF-α, IFN-γ), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus. Lupus. 2012;21(10):1105-1112.
29. Ziolkowska M, Koc A, Luszczykiewicz G, et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol. 2000;164(5):2832-2838. (Pubitemid 30115519)
30. Nogueira E, Hamour S, Sawant D, et al. Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol Dial Transplant. 2010;25(7):2209-2217.
31. Balato A, Schiattarella M, Di Caprio R, et al. Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway. J Eur Acad Dermatol Venereol. 2013;92(4):5-8.
32. Takahashi N, Matsumoto K, Saito H, et al. Impaired CD4 and CD8 effector function and decreased memory T cell populations in ICOS-deficient patients. J Immunol. 2009;182(9):5515-5527.
33. Nishimoto S, Kotani H, Tsuruta S, et al. Th17 cells carrying TCR recognizing epidermal autoantigen induce psoriasis-like skin inflammation. J Immunol. 2013;191(6):3065-3072.
34. Dianzani U, Chiocchetti A, Ramenghi U. Role of inherited defects decreasing Fas function in autoimmunity. Life Sci. 2003;72(25):2803-2824. (Pubitemid 36410337)
35. Orilieri E, Cappellano G, Clementi R, et al. Variations of the perforin gene in patients with type 1 diabetes. Diabetes. 2008;57(4):1078-1083.
36. Comi C, Fleetwood T, Dianzani U. The role of T cell apoptosis in nervous system autoimmunity. Autoimmun Rev. 2012;12(2):150-156.
37. Chang DW, Xing Z, Pan Y, et al. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J. 2002;21(14):3704-3714. (Pubitemid 34787044)
38. Yu Y, Iclozan C, Yamazaki T, et al. Abundant c-Fas-associated death domain-like interleukin-1-converting enzyme inhibitory protein expression determines resistance of T helper 17 cells to activation-induced cell death. Blood. 2009;114(5):1026-1028.
39. Kyttaris VC, Zhang Z, Kuchroo VK, Oukka M, Tsokos GC. Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice. J Immunol. 2010;184(9):4605-4609.
40. Kyttaris VC, Kampagianni O, Tsokos GC. Treatment with anti-interleukin 23 antibody ameliorates disease in lupus-prone mice. Biomed Res Int. 2013;2013:861028.
41. Bossù P, Neumann D, Del Giudice E, et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc Natl Acad Sci USA. 2003;100(24):14181-14186. (Pubitemid 37499211)
42. Lalor SJ, Dungan LS, Sutton CE, Basdeo SA, Fletcher JM, Mills KH. Caspase-1-processed cytokines IL-1β and IL-18 promote IL-17 production by gammadelta and CD4 T cells that mediate autoimmunity. J Immunol. 2011;186(10):5738-5748.
43. Veenbergen S, Smeets RL, Bennink MB, et al. The natural soluble form of IL-18 receptor beta exacerbates collagen-induced arthritis via modulation of T-cell immune responses. Ann Rheum Dis. 2010;69(1):276-283.
44. Millward JM, Løbner M, Wheeler RD, Owens T. Inflammation in the central nervous system and Th17 responses are inhibited by IFN-gamma-Induced IL-18 binding protein. J Immunol. 2010;185(4):2458-2466.
45. Kelchtermans H, Schurgers E, Geboes L, et al. Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferongamma and counteraction by interferon-gamma. Arthritis Res Ther. 2009;11(4):R122.
46. Yang XO, Chang SH, Park H, et al. Regulation of inflammatory responses by IL-17F. J Exp Med. 2008;205(5):1063-1075. (Pubitemid 351679682)
47. Shao S, He F, Yang Y, Yuan G, Zhang M, Yu X. Th17 cells in type 1 diabetes. Cell Immunol. 2012;280(1):16-21.
48. Nalbandian A, Crispín JC, Tsokos GC. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol. 2009;157(2):209-215.
49. Genovese MC, Van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010;62(4):929-939.
50. Hueber W, Patel DD, Dryja T, et al Psoriasis Study Group; Rheumatoid Arthritis Study Group; Uveitis Study Group. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72.